Seeking Alpha
03 Nov 2025, 22:17 UTC · 46w ago
Verdict
Source says Upgrade. We score KRYS +1.00 across four claims.
Score confirms the headline.
Upgrade
Rating stated in the headline
+1.00strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
Vyjuvek generated $97.8M in Q3 revenue with a 96% gross margin.
More positive than 99% of claims this week
The FDA granted a Platform Technology Designation for Krystal's HSV-1 vector.
So whatThis accelerates the development timeline for multiple future pipeline candidates, increasing long-term enterprise value.
Continue reading
5 related stories
More positive than 98% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 93% of claims this week
Vyjuvek received a new label allowing for at-home use.
More positive than 86% of claims this week
The company is advancing pipeline therapies for cystic fibrosis and DEB eye therapy.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Strong Q3 results, high margins, new label expansion, and positive FDA designations for their gene therapy platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
2h ago
+72.7%
Price agrees with the score
$341.75 vs $197.85 close before publication (Nov 3) · not market-adjusted
KRYS chart →
